Plaintiff
17 cases as plaintiff.
Veloxis Pharmaceuticals, Inc. is a specialty pharmaceutical company headquartered in Cary, North Carolina. Founded in 2002 as a spin-off from H. Lundbeck A/S, the company was acquired by the Japanese firm Asahi Kasei in March 2020 for approximately $1.3 billion. Veloxis now operates as a wholly-owned indirect subsidiary and part of Asahi Kasei's global healthcare business. Publicly available information from 2024 indicates the company has approximately 116 employees.
Veloxis is an operating company focused on the development and commercialization of immunosuppressive drugs for organ transplant recipients. Its primary product is ENVARSUS XR® (tacrolimus extended-release tablets), a once-daily medication used to prevent organ rejection in kidney transplant patients. The company utilizes its proprietary MeltDose® drug delivery technology, which is designed to improve the absorption and bioavailability of certain oral medications. Veloxis is also developing a pipeline product, VEL-101 (pegrizeprument), an investigational agent for the prevention of acute rejection in solid organ transplant recipients.
The company's patent litigation history shows it acts as an enforcement entity for its own products. All six of its tracked patent cases have been filed as a plaintiff, with zero cases as a defendant. This posture is typical of a pharmaceutical brand owner suing generic drug manufacturers for patent infringement under the Hatch-Waxman Act. All of its lawsuits have been filed in the U.S. District Court for the District of Delaware, a common venue for pharmaceutical patent litigation.
The defendants in Veloxis's lawsuits are generic pharmaceutical manufacturers, including Glenmark Pharmaceuticals Inc., Alkem Laboratories Ltd., Sun Pharmaceutical Industries Ltd., and Accord Healthcare, Inc. These cases are consistent with a strategy of defending the patent portfolio of its key commercial product, ENVARSUS XR, against companies seeking to market generic versions. The lawsuits allege infringement of patents covering the drug product and its formulation.
Watchlist
Email-only, free, anonymous. We'll notify you when Veloxis Pharmaceuticals, Inc. files another patent-infringement lawsuit. One-click unsubscribe from any alert.
This is an Abbreviated New Drug Application (ANDA) case filed by Veloxis Pharmaceuticals against Glenmark Pharmaceuticals in the District of Delaware. Filed in March 2026, the case is currently open.
This Hatch-Waxman Act litigation against Glenmark Pharmaceuticals is currently listed as ongoing.
This is an ongoing ANDA patent infringement case filed by Veloxis Pharmaceuticals, Inc. against Glenmark Pharms. Inc. in the District Court, Delaware.
This case asserts infringement of US Patent 11110081, among others, relating to Glenmark's ANDA for tacrolimus extended-release tablets. A stipulation and order regarding a stay was filed on February 2, 2026.
This case is currently active. Proceedings are in the early stages.
This appears to be an ANDA case concerning Envarsus XR® (tacrolimus extended-release tablets). The case is currently active.
This is an ongoing ANDA patent infringement case filed by Veloxis Pharmaceuticals, Inc. against Alkem Labs. Ltd. in the District Court, Delaware.
This case is currently active. Given the filing date, proceedings are likely in the discovery phase.
This case, filed on June 19, 2024, is currently at the 'Start Trial' stage in the District Court, D. Delaware.
Veloxis Pharmaceuticals, Inc. filed this action asserting several patents, including US Patent 11110081. The thirty-month stay deadline for this case is November 9, 2026.
The complaint alleged that the defendants' ANDA for generic tacrolimus extended-release tablets infringed on six Veloxis patents, including the '918 patent. Veloxis sought to block the manufacturing and marketing of the generic product.
This case alleges patent infringement due to the defendants' submission of an Abbreviated New Drug Application (ANDA) to the FDA, seeking to market generic tacrolimus extended-release tablets before the expiration of Veloxis's patents, including US11419823. Veloxis is seeking favorable judgment, an order preventing the defendants from manufacturing their ANDA products, damages, and litigation fees.
Veloxis Pharmaceuticals, Inc. filed suit alleging patent infringement due to the defendants' submission of Abbreviated New Drug Applications (ANDA) for generic tacrolimus extended-release tablets. Veloxis is seeking favorable judgment, an order preventing manufacturing, and damages.
This case was filed in response to Accord Healthcare's submission of an Abbreviated New Drug Application (ANDA) to the FDA, seeking approval to market generic versions of Veloxis's ENVARSUS XR prior to the expiration of several patents, including US 8664239. Veloxis alleges patent infringement, seeking to prevent the defendants from manufacturing their ANDA products and requesting damages if the products are launched.
This ongoing case involved a 'Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA)' filing on April 14, 2025, and continues with proposed protective orders and scheduling orders in August 2025.
This is an ongoing ANDA patent infringement case filed by Veloxis Pharmaceuticals, Inc. in the District Court, Delaware, with an unknown defendant.
Veloxis Pharmaceuticals, Inc. sued Accord Healthcare and Intas for patent infringement. The case was dismissed with prejudice via a consent judgment filed on January 24, 2024, enjoining Accord and Intas from infringement until the expiration of the patents-in-suit.